Sequome was founded by Eeshit Dhaval Vaishnav in 2022.

How much funding has Sequome raised?

Sequome has disclosed $10.6M raised across 1 round.

Where is Sequome headquartered?

Sequome is headquartered in South San Francisco, US.

Sequome

South San Francisco, US · Founded 2022 · Delaware corporation

Find your way into Sequome

Paths you didn't know you had: your email and LinkedIn already hold routes to the Sequome team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sequome uses AI to engineer biological sequences for developing therapeutics, based on its sequence-to-function model called Gene Genie. The company has collaborated with large pharmaceutical firms and Google DeepMind in the drug discovery and biotechnology space.

AI & Machine Learning Biotech Deep Tech

Founders & leadership

Sequome was founded in 2022 by Eeshit Dhaval Vaishnav.

Eeshit Dhaval VaishnavFounder

Reported raises · per SEC filings

Form D private placements

$10.6M disclosed across 1 round · 2025

▶$10.6MraisedJul 2025 · 2 investors · Other Technology

Rule 506(b)

Officers, directors & promoters on the filing

Eeshit Dhaval VaishnavExecutive Officer, Director, Promoter

Offering amount: $11.5M
Amount sold: $10.6M
First sale: Jun 2025
Incorporated: Corporation, Delaware, 2022
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 10

NucleomeNucleome develops 3D genomics technology to map genetic variants in the non-coding genome to the genes they dysregulate, with applications in understanding inflammatory diseases and discovering therapeutic targets. The company builds a data atlas of immune system dysregulation to enable development of genetically-informed therapeutics for inflammatory conditions.

CellanomeCellanome develops a live-cell analysis platform using CellCage technology to create controlled microenvironments that enable researchers to observe cell behavior and molecular changes over time. The platform generates structured multimodal data for life sciences researchers and biopharma companies focused on oncology, neuroscience, immunology, and aging research.

Alterome Therapeutics, Inc.Alterome is a clinical-stage precision oncology company developing small-molecule, alteration-specific cancer therapies, with two internally discovered drug candidates in the clinic. It focuses on hard-to-drug cancer targets such as mutant KRAS and mutant AKT E17K across malignancies including non-small cell lung, pancreatic, colorectal, endometrial, and breast cancers.

ImmunomeImmunome is a clinical-stage oncology company developing targeted cancer therapies, including antibody-drug conjugates (ADCs) and small molecules, to address unmet medical needs in cancers such as lymphoma and bladder cancer. It also acquires targeted oncology assets and advances them through manufacturing and clinical development.

SensomeSensome develops medical technology solutions at the intersection of engineering and life sciences, focusing on healthcare applications.

MyomeMyOme provides genomic insights and clinical genetic screening reports to help individuals and healthcare providers assess risks for hereditary conditions and make informed health decisions.

Noveome BiotherapeuticsNoveome is a clinical-stage biopharmaceutical company developing ST266, a multi-targeted secretome containing hundreds of biologically active proteins designed for neuroprotection, inflammation modulation, and tissue healing. The company is investigating ST266's potential across ophthalmology, neurology, dermatology, and other therapeutic areas.

FreenomeFreenome develops early-stage cancer detection technology using blood tests to identify cancer in its earliest, most treatable phases. The company serves healthcare providers and patients seeking preventive cancer screening solutions.

nChroma BionChroma Bio develops in vivo targeted delivery and genetic engineering technologies for genetic medicine applications. The company works with academic founders and institutional investors focused on advancing gene therapy treatments.

Simmunome Inc.Simmunome provides computational biology and mechanistic modeling solutions for drug development across all phases, helping pharmaceutical companies understand disease pathways, validate drug targets, predict efficacy, and optimize patient stratification.

Companies working in the same space as Sequome.

Frequently asked questions

What does Sequome do?: Sequome uses AI to engineer biological sequences for developing therapeutics, based on its sequence-to-function model called Gene Genie. The company has collaborated with large pharmaceutical firms and Google DeepMind in the drug discovery and biotechnology space.
Who founded Sequome?: Sequome was founded by Eeshit Dhaval Vaishnav in 2022.
How much funding has Sequome raised?: Sequome has disclosed $10.6M raised across 1 round.
Where is Sequome headquartered?: Sequome is headquartered in South San Francisco, US.